請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35592完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳漢忠,林欽塘 | |
| dc.contributor.author | De-Kuan Chang | en |
| dc.contributor.author | 張德寬 | zh_TW |
| dc.date.accessioned | 2021-06-13T07:00:03Z | - |
| dc.date.available | 2008-08-12 | |
| dc.date.copyright | 2005-08-12 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-27 | |
| dc.identifier.citation | Adams, G. P., Schier, R. (1999) Generating improved single-chain Fv molecules for tumor targeting. Immunol Methods, 231: 249–260
Aina, O. H., Sroka, T. C., Chen, M. L., Lam, K. S. (2002) Therapeutic cancer targeting peptides. Biopolymers, 66: 184–199 Aina O. H., Marik, J., Liu, R., Lau, D. H., Lam, K. S. (2005) Identification of novel targeting peptides for human ovarian cancer cells using “one-bead one-compound” combinatorial libraries. Mol. Cancer Ther., 4: 806-813 Allen, T. M., Chonn, A. (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett, 223: 42-46 Allen, T. M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta, 1066: 29-36 Allen, T. M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2: 750-763 American Cancer Society. Cancer facts and figures. (American Cancer Society, Atlanta, Georgia, 2002) Blume, G., Cevc, G. (1990) Liposomes for the sustained drug release in vivo. Biochim Biophys Acta, 1029: 91-7 Boyle, P., Gandini, S., Gray, N. (2000) Epidemiology of lung cancer: a century of great success and ignominious failure. In: Hansen H, editor(s). IASLC Textbook of Lung Cancer. London: Martin Dunitz, 13-26 Brown, C. K., Modzelewski, R. A., Johnson, C. S., Wong, M. K. (2000) A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg. Oncol., 7: 743–749 Bruce A. C., Thomas G. R. (2005) Chemotherapy and the war on cancer. Nature Reviews Cancer, 5: 65-72 Cersosimo, R. J. (2002) Lung cancer: a review. Am. J. Health Syst. Pharm,. 59: 611–642 Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51: 691-743 Dvorak, H. F., Nagy, J. A., Dvorak, A. M. (1991) Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77–85 Frankel, A. E., FitzGerald, D., Siegall, C., Press, O. W. (1996) Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. Cancer Res., 56: 926–932 Fry W. A., Phillips J. L., Menck H.R. (1999) Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer, 86: 1867–1876 Fukuda, M. N., Ohyama, C., Lowitz, K., Matsuo, O., Pasqualini, R., Ruoslahti, E., Fukuda, M. (2000) A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res., 60: 450–456 Gabizon, A., Papahadjopoulos, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA, 85: 6949-53 Gregoriadis G., Wills E. J., Swain C. P., Tavill A. S. (1974) Drug-carrier potential of liposomes in cancer chemotherapy. Lancet, 1: 1313-1316 Hall, B., Boroughs, J., Kobrin, B. (1998) A novel tumor-specific human single-chain Fv selected from an active specific immunotherapy phage display library. Immunotechnology, 4: 127–140 Hirohashi, S., Sugimura, T. (1991) Genetic alterations in human gastric cancer. Cancer Cells, 3: 49-52 Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., Thorpe, P. E. (1997). Tumor infraction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275: 547-550. Ihde D.C. (1992) Chemotherapy of lung cancer. New England Journal Medicine, 327: 1434–1441 Isobe, T., Herbst, R. S., Onn, A. (2005) Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol, 32(3): 315-28 Ivanenko, V. V., Felici, F., Menon, A. G. (1999) Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim Biophys Acta, 1448: 463–472 Jain, R. K. (1997) The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation, 4: 1–23 Jemal A., Thomas A., Murray T., Thun M. (2002) Cancer statistics CA Cancer J Clin, 52: 23-47 Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C.W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., Wahl, R. L. (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol, 14(7): 1974–1981 Kim, E. S., Khuri, F. R., Herbst, R. S. (2001) Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol, 13: 506–513 Klibanov, A. L., Maruyama, K., Torchilin, V. P., Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett, 268: 235-7 Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O. P., Heikkila, P., Kantor, C., Gahmberg, C. G., Salo, T., Konttinen, Y. T., Sorsa, T., Pasqualini, R., Ruoslahti, E. (1999) Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol, 17: 768–774 Kolonin, M., Pasqualini, R., Arap, W. (2001) Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol, 5: 308–313 Lee, T. Y., Wu, H. C., Tseng, Y. L., Lin, C. T. (2004) A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res., 64: 8002-8008 Lewis, J. P., Denardo, G. L.; Denardo, S. J. (1995) Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma, 14(2): 115–120 Levy, S. E., Hyman, S. L. (2005) Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev, 11: 131-142 Li, B., Tom, J. Y., Oare, D., Yen, R., Fairbrother, W. J., Wells, J. A., Cumningham, B. C. (1995) Minimization of a polypeptide hormone. Science, 270: 1657-1660 Marchio, S., Lahdenranta, J., Schlingemann, R. O., Valdembri, D., Wesseling, P., Arap, M. A., Hajitou, A., Ozawa, M. G., Trepel, M., Giordano, R. J., Nanus, D. M., Dijkman, H. B., Oosterwijk, E., Sidman, R. L., Cooper, M. D., Bussolino, F., Pasqualini, R., Arap, W. (2004) Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell, 5: 151-62 Neumeister, P., Eibl, M., Zinke-Cerwenka, W., Scarpatetti, M., Sill, H., Linkesch, W. (2001) Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol, 80: 119–120 Ostoros, G., Kovacs, G., Szondy, K., Dome, B. (2005) New therapies for non-small cell lung cancer. Orv Hetil, 146(21): 1135-41 Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., Martin, F. J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464 Parkin, D. M., et al. (2001) Cancer burden in the year 2000. The global picture. Eur. J. Cancer, 37: S4–S66 Parmley, S. F., Smith, G. P. (1988) Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene, 73: 305 Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Nelp, W. B., Glenn, S., Fisher, D. R., Porter, B., Matthews, D. C., Gooley, T. (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. The Lancet, 346: 336–340 Rebecca S. F. (2003) Overview of targeted therapies for cancer. American Journal of Health-System Pharmacy, 60: S4-S10 Romanov, V. I., Durand, D. B., Petrenko, V. A. (2001) Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion. Prostate, 47: 239–251 Romanov, V. I. (2003). Phage display selection and evaluation of cancer drug targets. Curr. Cancer Drug Targets, 3: 119–129 Senior, J. H. (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst, 3: 123-93 Senior, J., Delgado, C., Fisher, D., Tilcock, C., Gregoriadis, G. (1991) Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta, 1062: 77-82 Shockely, T. R., Lin, K., Nagy J. A., Tompkins, R. G., Dvorak, H. F., Yarmush, M. L. (1991) Penetration of tumor tissue by antibodies and other immunoproteins. Ann NY Acad Sci, 618: 367–382 Sievers, E. L., Linenberger, M. (2001) Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol, 13: 522–527 Sioud, M., Forre, O., Dybwad, A. (1996) Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Clin. Immunol. Immunopathol., 79: 105–114 Thomas, G. E., Esteban, J. M., Raubitshek, A., Wong, J. Y. (1995) gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies. Int J Radiation Oncol Biol Phys, 31: 529–534 Uenka, H. (2005) Chemotherapy for advanced non-small cell lung cancer. Gan To Kagaku Ryoho, 32(6): 770-6 Viti, F., Tarli, L., Giovannoni, L., Zardi, L., Neri, D. (1999). Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumor angiogenesis. Cancer Res., 59: 347-352. Weinstein, J. N. (1984) Liposomes as drug carriers in cancer therapy. Cancer Treat Rep., 68: 127−135 Wong, C., Waibel, R., Sheets, M., Mach, J., Finnern, R. (2001) Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol Immunother, 50: 93–101 Woodle, M. C., Lasic, D. D. (1992) Sterically stabilized liposomes. Biochim Biophys Acta, 1113: 171-99 Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., Dower, W. J. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science, 273: 458-463 Wu, H. C., Huang, Y. L., Chao, T. T., Jan, J. T., Huang, J. L., Chiang, H. Y., King, C. C., Shaio, M. F. (2001) Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J Clin Microbiol, 39: 977-82 Wu, H. C., Jung, M. Y., Chiu, C. Y., Chao, T. T., Lai, S. C., Jan, J. T., Shaio, M. F. (2003) Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol, 84: 2771-2779 Wu, H. C., June, M. Y., Chiu, C. Y., Lai, S. C., Jan, J. T., Shaio, M. F. (2003) Identification of serotype-specific B-cell epitope of dengue virus type 2 and detection of dengue immunized serum samples by epitope-based peptide antigen. J. Gen. Virol., 84: 2271-2279 Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R., Dewhirst, M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res., 53: 3765−3770 Wu, P., Leinonen, J., Koivunen, E., Lankinen, H. (2000) Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem, 267: 6212 Yokoba, M., Yanase, N., Masuda, N. (2005) New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents. Gan To Kagaku Ryoho, 32(6): 783-8 Young, A. C., Valadon, P., Casadevall, A., Scharff, M. D., Sacchettini, J. C. (1997) The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes. J. Mol. Biol., 274: 622-634 Zhang, J., Spring, H., Schwab, M. (2001) Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett, 171: 153–164 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35592 | - |
| dc.description.abstract | 全世界，每年約有一千萬人被診斷出患有癌症，而一年之中，更有超過六百萬人死於此疾病。而其中最為普遍的癌症分別為，佔12.3%的肺癌、10.4%的乳癌、以及9.4%的結腸直腸癌。肺癌於工業化國家中擁有高致死率，是所有因癌症死亡的病例中最為顯著的。人們患有非小細胞肺癌的病患其五年的存活率低於15%。缺乏癌細胞專一性標的物質一直是化學療法中的一重大問題，由於不具有專一性而使得副作用的產生，進而限制了藥物的劑量而無法根除癌細胞。在此研究中，我們運用噬菌體展示法，分離出能專一性結合非小細胞肺癌之十二個胺基酸胜肽。表現此特殊胜肽〈P5-2〉的噬菌體〈PC5-2〉具有專一性結合至非小細胞肺癌細胞株，且不會與正常細胞有結合現象。而針對移植非小細胞肺癌的SCID老鼠，此PC5-2噬菌體能專一性地瞄準腫瘤組織結合。此外，PC5-2噬菌體的導向能力，能進一步地被合成的P5-2胜肽所競爭而失去結合能力。更甚之，當將包含VNB抗癌藥物的微脂體連接P5-2胜肽〈P5-2-Lipo-VNB〉後，抑制腫瘤的生長能力較只帶有VNB的微脂體〈Lipo-VNB〉佳，且不會產生副作用。這些結果都指出P5-2胜肽將抗癌藥物送到癌組織並加強了藥物殺死SCID老鼠中肺癌組織的效力。此腫瘤專一性胜肽深具標的治療肺癌的潛力，並且可以發展肺癌的診斷試劑。 | zh_TW |
| dc.description.abstract | The most common cancers worldwide are lung (12.3 % of all cancers), breast (10.4 %) and colorectal cancer (9.4 %). Lung cancer is the predominant cause of cancer deaths in industrialized countries with a high death rate. The five-year survival rate is less than 15 % for patients with advanced non-small-cell lung cancer (NSCLC). Lack of tumor specificity remains a major problem with chemotherapies in that side effects prevent the delivery of essential dosages of drugs to eliminate majority cancer cells. In this report, we describe the isolation of a 12-mer peptide (P5-2) specifically binding to NSCLC from peptide-presenting phage libraries. The phage displayed P5-2 (PC5-2) were able to bind to NSCLC cell lines and did not bind to normal cells. In SCID mice bearing NSCLC xenografts, the PC5-2 could target to the tumor mass specifically. The homing activity of PC5-2 clones could be further competitively inhibited by synthetic P5-2. Furthermore, the P5-2-Lipo-vinorelbine (VNB) repressed tumor growth better than Lipo-VNB and without side effect. These results indicate that P5-2 enhanced the therapeutic efficacy of the drug against lung cancer xenografts in SCID mice. This tumor-specific peptide has a potential for targeted drug delivery to treat lung cancer and may be useful for designing targeted gene transfer vectors as well as diagnostic tools for this disease. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T07:00:03Z (GMT). No. of bitstreams: 1 ntu-94-R92444003-1.pdf: 2749148 bytes, checksum: a28f7944b0f54458f6db397610534447 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 中文摘要……………………………1
Abstract……………………………2 Introduction………………………3 Materials and methods…………10 Results……………………………18 Discussion ………………………23 Figures……………………………29 Reference…………………………41 | |
| dc.language.iso | en | |
| dc.title | 肺癌專一性標的胜肽之尋找及標的治療之發展 | zh_TW |
| dc.title | Identification of a Novel Peptide Specifically Binding to Lung Cancer for Targeted Therapy | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張明富,周玉山,張久瑗 | |
| dc.subject.keyword | 腫瘤標的胜肽,肺癌, | zh_TW |
| dc.subject.keyword | tumor-homing peptides,NSCLC, | en |
| dc.relation.page | 50 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-07-28 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| 顯示於系所單位： | 病理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 目前未授權公開取用 | 2.68 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。